Business
AstraZeneca chief quits CSL board over $50 billion acquisition – Sydney Morning Herald
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
AstraZeneca announced its planned acquisition of Alexion for $US39 billion ($50.4 billion) in the second week of December, with Mr Soriot telling his investors the deal would allows us to enhance our presence in immunology.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player.
CSL, which is producing doses of AstraZenecas COVID-19 vaccine in Australia, told investors last year that Mr Soriots appointment did not look…
-
Noosa News23 hours agoQueensland man sentenced to four years imprisonment after string of terror offences
-
Noosa News23 hours agoBali traveller sparks urgent measles alert across Queensland
-
Business23 hours agoThe best ASX ETFs for compounding wealth until 2040
-
Noosa News22 hours agoMeasles alert issued south of Brisbane after traveller tests positive